Evolocumab and alirocumab have been approved based on a randomised trial. We analysed the outcomes reported in the two trials to develop an original framework of comparative assessment that uses the restricted mean survival time (RMST). The objective was to show that, in the context of a narrative review, the RMST can be an efficient though simple tool to make indirect comparisons. For each cohort of patients (13,784 patients given evolocumab, 9,462 given alirocumab, 23,242 controls; results expressed in months of event-free survival), we determined the values of RMST with 95% confidence intervals [CI] (evolocumab: 33.48, 95%CI: 33.45 to 33.50; alirocumab: 33.89, 95%CI: 36.86 to 33.92). These results, along with those of the control groups, were analysed and interpreted narratively. A univariate statistics was conducted; no network meta-analysis was done. The experience presented herein indicates that a framework of evidence assessment focused on RMST is a worthwhile option.